Business Context and Reporting Period
Company: Organogenesis Holdings Inc. (ORGO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A regenerative medicine company focused on advanced wound care and surgical/sports medicine products. The company operates in a single segment and sells products to hospitals, wound care centers, and physician offices.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $150.9M | $115.2M | $338.6M | $355.4M |
| Net Product Revenue | $150.5M | $115.2M | $338.0M | $355.4M |
| Net Income (Loss) | $21.6M | $12.3M | $(6.7M) | $(6.8M) |
| Net Income Attributable to Common | $14.5M | $12.3M | $(15.1M) | $(6.8M) |
| Diluted EPS | $0.11 | $0.09 | $(0.12) | $(0.05) |
| Operating Cash Flow (9M) | $(49.7M) vs $3.3M | |||
| Cash & Equivalents (Sep 30, 2025) | $63.7M | |||
| Working Capital (Sep 30, 2025) | $205.1M | |||
| Debt Obligations | $0 outstanding borrowings |
Liquidity: The company reported $63.7 million in cash and cash equivalents as of September 30, 2025. It has a $75.0 million revolving credit facility available (reduced from $125.0 million in October 2025) with no outstanding borrowings.
Material Changes vs. Prior Period
- Revenue Growth (Q3): Net product revenue increased 31% year-over-year to $150.5M, driven by a 31% increase in Advanced Wound Care revenue and a 25% increase in Surgical & Sports Medicine revenue.
- Revenue Decline (9M): Despite Q3 growth, nine-month revenue decreased 5% to $338.0M. Advanced Wound Care revenue fell 6% due to customer behavior disruption from delayed Local Coverage Determination (LCD) implementations, partially offset by new product introductions.
- Profitability: The company returned to profitability in Q3 2025 with $21.6M net income, compared to a net loss of $6.7M for the full nine-month period. This contrasts with a net loss of $6.8M for the nine months ended September 30, 2024.
- Asset Write-downs: The company recorded a $9.2M write-down to fair value for an asset held for sale during the nine months ended September 30, 2025. In the prior year period, significant impairments included $18.8M for property/construction and $4.0M for internal-use software.
- Cash Flow: Operating cash flow turned negative, using $49.7M in the first nine months of 2025 compared to providing $3.3M in the same period in 2024. This was primarily due to a $64.3M increase in accounts receivable and a $15.0M increase in inventory.
Guidance, Outlook, Risks, and Unusual Items
- ReNu Clinical Trial Update: The second Phase 3 Randomized Controlled Trial (RCT) for ReNu (knee osteoarthritis) did not achieve statistical significance for its primary endpoint, though it showed numerical improvement. The company plans to meet with the FDA in December 2025 to discuss a Biologics License Application (BLA) using combined data from both Phase 3 studies.
- Regulatory Risks (LCDs): Seven Medicare Administrative Contractors (MACs) finalized Local Coverage Determinations (LCDs) that classify over 200 products, including several of the company's (PuraPly, Dual, Matrix), as "non-covered" for diabetic foot ulcers and venous leg ulcers. Implementation was delayed to January 1, 2026. If implemented, this could materially impact revenue.
- Medicare Payment Rules: New CMS rules for 2026 regarding Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) will standardize payment rates for skin substitute products, which could materially affect utilization and profitability.
- Debt Covenant Amendments: In October 2025, the company amended its credit agreement to reduce the revolving facility to $75M, remove the Fixed Charge Coverage Ratio covenant, and add a minimum Interest Coverage Ratio covenant (3x) and a Capital Expenditures covenant.
- Unusual Items: Q3 2025 included $377k in grant income related to the Smithfield Facility. The company also recorded $922k in write-downs for assets held for sale in Q3.
Investor Verification Checklist
- ReNu BLA Strategy: Verify the FDA's response to the proposed combined efficacy analysis from the two Phase 3 trials and the likelihood of approval given the second trial's lack of statistical significance.
- Reimbursement Impact: Assess the potential revenue impact of the January 1, 2026, implementation of the new LCDs and the 2026 CMS payment rate changes for skin substitutes.
- Cash Burn Rate: Monitor the trend in operating cash flow, specifically the drivers behind the $64M increase in accounts receivable and $15M increase in inventory.
- Debt Covenants: Confirm ongoing compliance with the new Interest Coverage Ratio and Capital Expenditures covenants established in the October 2025 credit amendment.
- Asset Sale: Track the progress of the sale of the Canton, MA building classified as "held for sale" and any further fair value adjustments.